NEW YORK, NY / ACCESSWIRE / September 20, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zynerba Pharmaceuticals ("Zynerba" or "the Company") (ZYNE). Investors who purchased Zynerba stock are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/zyne.
The investigation concerns whether Zynerba and certain of its officers and/or directors have violated federal securities laws.
On September 18, 2019, Zynerba issued a press release announcing results from its open-label Phase 2 BELIEVE 1 clinical trial evaluating topical gel Zygel (ZYN002) in children and adolescents with developmental and epileptic encephalopathies. While Zynerba stated that Zygel was well-tolerated, it also disclosed that the rate of treatment-emerged adverse events was 96% and that "two [serious adverse events] (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment." On this news, Zynerba's stock price fell $2.46 per share, or 21.77%, to close at $8.84 per share on September 18, 2019.
If you are aware of any facts relating to this investigation, or purchased Zynerba shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/zyne. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: